Amoxicillin for childhood pneumonia: 3 days versus 7 days

Area of Science:

• Pediatric infectious diseases
• Clinical pharmacology
• Respiratory medicine

Background:

• Community-acquired pneumonia (CAP) is a leading cause of childhood illness globally.
• Optimal antibiotic treatment duration and dosage for pediatric CAP remain debated.
• Previous guidelines suggested longer courses, potentially leading to overuse.

Purpose of the Study:

• To determine if shorter amoxicillin durations (5 vs 7 days) are non-inferior to longer durations for pediatric CAP.
• To assess if standard amoxicillin doses are non-inferior to higher doses for pediatric CAP.
• To evaluate the efficacy and safety of different amoxicillin regimens in children with CAP.

Main Methods:

• A factorial, non-inferiority randomized controlled trial (RCT) involving children diagnosed with CAP.
• Participants were randomized to receive either 5 or 7 days of amoxicillin, and standard or high-dose amoxicillin.
• Outcomes included clinical cure rates, treatment failure, and adverse events.

Main Results:

• Five-day amoxicillin courses were non-inferior to 7-day courses for treating pediatric CAP.
• Standard-dose amoxicillin was non-inferior to high-dose amoxicillin.
• No significant differences in treatment failure or adverse events were observed between the groups.

Conclusions:

• Shorter duration (5 days) and standard dose of amoxicillin are effective for pediatric community-acquired pneumonia.
• These findings support revising treatment guidelines to optimize antibiotic use and reduce unnecessary exposure.
• The study provides evidence for safer and more efficient antibiotic stewardship in children.